Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01096407 · ClinicalTrials.gov registry record
Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 5
- Enrollment target
NCT01096407 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 5 participants.
The verdict
NCT01096407 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Learning about pain in patients with cancer receiving paclitaxel may help plan treatment and may help patients live more comfortably. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to muscle and joint pain. PURPOSE: This phase I trial is studying the role of biomarkers in muscle pain and joint pain in patients with solid tumors receiving paclitaxel.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01096407
The ClinicalTrials.gov registry entry for NCT01096407 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01096407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01096407 about?
NCT01096407 is a clinical study titled "Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel". RATIONALE: Learning about pain in patients with cancer receiving paclitaxel may help plan treatment and may help patients live more comfortably. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to muscle and joint...
What is the current status of trial NCT01096407?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2009-11. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01096407?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT01096407?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.